Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS): 40 pipeline candidates · 15 upcoming catalysts · ~17 mo cash runway · 28 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
17.3 months
0% dilution
Lead: Phase 3
40 candidates
15 upcoming, next in ~13d
0 buys · 6 sells (180d)
A transparent, data-derived signal for Arcus Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.0B
Cash
$201.0M
Quarterly Burn
$138.0M
Runway
17.3 mo
Revenue
$17.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (40 candidates)
| Drug | Phase |
|---|---|
| AB308 | Phase 1 |
| AB598 | Phase 1 |
| AB680 | Phase 1 |
| AB801 | Phase 1 |
| APX005M | Phase 1 |
| Cabozantinib | Phase 1 |
| Casdatifan | Phase 1 |
| casdatifan (AB521) | Phase 3 |
| Domvanalimab | Phase 1 |
| Enzalutamide | Phase 1/Phase 2 |
Showing 10 of 40 candidates. Sign up for full pipeline.
Upcoming Catalysts (15)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
209
Total value held
$2.51B
| Holder | Shares | Value |
|---|---|---|
| gilead sciences, inc. | 31,424,760 | $678.8M |
| blackrock, inc. | 15,226,475 | $328.9M |
| vanguard capital management llc | 7,713,450 | $166.6M |
| wellington management group llp | 6,089,516 | $131.5M |
| state street corp | 5,412,901 | $116.9M |
| suvretta capital management, llc | 5,030,993 | $108.7M |
| vanguard portfolio management llc | 4,272,056 | $92.3M |
| marshall wace, llp | 3,761,437 | $81.2M |
| geode capital management, llc | 2,252,367 | $48.7M |
| fisher asset management, llc | 2,190,404 | $47.3M |
Showing top 10 of 209 institutional holders of Arcus Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Arcus Biosciences, Inc.'s pipeline?
Arcus Biosciences, Inc. (RCUS) has 40 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Arcus Biosciences, Inc.'s lead drug candidate?
Arcus Biosciences, Inc.'s most advanced tracked candidate is AB308 (Phase 1) for Advanced Solid Tumor.
What is Arcus Biosciences, Inc.'s next catalyst?
Arcus Biosciences, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: PRE-surgical NEOadjuvant Sandwich Immunotherapy With HIF inhibiTion in Renal Cell Carcinoma (PRENEOS" — expected July 1, 2026.
What is Arcus Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Arcus Biosciences, Inc. has approximately 17.3 months of cash runway.
What is Arcus Biosciences, Inc.'s market capitalization?
Arcus Biosciences, Inc.'s market capitalization is approximately $3.0B.
Get the full picture on Arcus Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.